Targeting TR4 nuclear receptor-mediated p21 downregulation to increase apoptosis for reverse of the Enzalutamide-resistance in prostate cancer

Background: Enzalutamide (enz), also known as MDV3100, is a crucial treatment for advanced Castration-Resistant Prostate Cancer (CRPC). However, many patients develop enz resistance, leading to disease progression and recurrence. Testicular Nuclear Receptor-4 (TR4) has been implicated in regulating prostate cancer initiation, progression, metastasis and radiosensitivity. p21, a suppressor of cell growth, is crucial in caspase-activated apoptosis through both p53-dependent and -independent pathways. This study aimed to explore how TR4 contributes to enz-resistance in CRPC and the involvement of p21. Methods: Enz-resistant cell lines were generated by culturing C4-2 cells with increasing enz doses from 10 µM to 80 µM for 100 days. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay (MTS) and Immunohistochemistry (IHC)-morphology assay confirmed the establishment of resistant cells. After TR4 knockdown and overexpression, Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Western Blot (WB) were used to detect TR4 and p21 expression changes and flow cytometry was employed to assess apoptosis. Results: C4-2 MDV-R cells were spindle-shaped and had a lower apoptosis rate than parental C4-2 cells under enz treatment. TR4 expression was elevated in C4-2 MDV-R cells. Overexpressing TR4 decreased the apoptosis rate of C4-2 cells treated with 25 µM enz, while knocking down TR4 increased it. Simultaneously, TR4 negatively regulated p21 expression. Knocking down TR4 in C4-2 MDV-R cells enhanced apoptosis during enz treatment. Conclusions: TR4 could be a potential therapy target in combination with enz as the promising treatment for CRPC.

TR4; p21; Enzalutamide; CRPC

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023; 73: 17–48.

[2] Choi E, Buie J, Camacho J, Sharma P, de Riese WTW. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Research and Reports in Urology. 2022; 14: 87–108.

[3] Turco F, Gillessen S, Cathomas R, Buttigliero C, Vogl UM. Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs. Research and Reports in Urology. 2022; 14: 339–350.

[4] Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. Journal of Clinical Oncology. 2023; 41: 4267–4278.

[5] Zheng Z, Li J, Liu Y, Shi Z, Xuan Z, Yang K, et al. The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer. Cancers. 2022; 14: 4877.

[6] Vogelzang NJ. Enzalutamide—a major advance in the treatment of metastatic prostate cancer. The New England Journal of Medicine. 2012; 367: 1256–1257.

[7] Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine. 2012; 367: 1187–1197.

[8] Nelson WG, Yegnasubramanian S. Resistance emerges to second-generation antiandrogens in prostate cancer. Cancer Discovery. 2013; 3: 971–974.

[9] Liu Y, Ma L, Li M, Tian Z, Yang M, Wu X, et al. Structures of human TR4LBD-JAZF1 and TR4DBD-DNA complexes reveal the molecular basis of transcriptional regulation. Nucleic Acids Research. 2023; 51: 1443–1457.

[10] Wang H, Zhu S, Zhou Z, Wang Z, Zhuang W, Xue D, et al. TR4 worsen urosepsis by regulating GSDMD. European Journal of Medical Research. 2024; 29: 151.

[11] Hu L, Sun Y, Luo J, He X, Ye M, Li G, et al. Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression. Oncogene. 2020; 39: 1891–1903.

[12] Chen D, Chou FJ, Chen Y, Tian H, Wang Y, You B, et al. Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity. Cancer Letters. 2020; 495: 100–111.

[13] Chen B, Yu S, Ding X, Jing C, Xia L, Wang M, et al. The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer. Cancer Gene Therapy. 2014; 21: 411–415.

[14] Zhu J, Qin P, Cao C, Dai G, Xu L, Yang D. Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer. Oncology Reports. 2021; 45: 963–974.

[15] Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Research. 2024; 52: D174–D182.

[16] Yehya A, Ghamlouche F, Zahwe A, Zeid Y, Wakimian K, Mukherji D, et al. Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo. Cancer Drug Resistance. 2022; 5: 667–690.

[17] Yao Y, Chen X, Wang X, Li H, Zhu Y, Li X, et al. Glycolysis related lncRNA SNHG3/miR-139-5p/PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance. International Journal of Biological Macromolecules. 2024; 260: 129635.

[18] Gao K, Li X, Ni J, Wu B, Guo J, Zhang R, et al. Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer. Cancer Letters. 2023; 566: 216247.

[19] You X, Huang S, Wang X, Yi C, Gong N, Yu J, et al. Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: a systematic review. Frontiers in Endocrinology. 2022; 13: 1125838.

[20] Chan JM, Zaidi S, Love JR, Zhao JL, Setty M, Wadosky KM, et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science. 2022; 377: 1180–1191.

[21] Cheng C, Wang J, Xu P, Zhang K, Xin Z, Zhao H, et al. Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer. Nature Cancer. 2022; 3: 565–580.

[22] Han M, Li F, Zhang Y, Dai P, He J, Li Y, et al. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer. Cancer Cell. 2022; 40: 1306–1323.e8.

[23] Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017; 355: 78–83.

[24] Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017; 355: 84–88.

[25] Somanath PR, Chernoff J, Cummings BS, Prasad SM, Homan HD. Targeting P21-activated kinase-1 for metastatic prostate cancer. Cancers. 2023; 15: 2236.

[26] Koyanagi A, Kotani H, Iida Y, Tanino R, Kartika ID, Kishimoto K, et al. Protective roles of cytoplasmic p21Cip1/Waf1 in senolysis and ferroptosis of lung cancer cells. Cell Proliferation. 2022; 55: e13326.

[27] Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: new insights into tumour biology and immune modulation. World Journal of Gastroenterology. 2018; 24: 3709–3723.

[28] Sun X, Hu Y, Wu J, Shi L, Zhu L, Xi PW, et al. RBMS2 inhibits the proliferation by stabilizing P21 mRNA in breast cancer. Journal of Experimental & Clinical Cancer Research. 2018; 37: 298.

[29] Zhang L, Chen J, Ning D, Liu Q, Wang C, Zhang Z, et al. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21. Journal of Experimental & Clinical Cancer Research. 2019; 38: 101.

[30] Kim E, Liu NC, Yu IC, Lin HY, Lee YF, Sparks JD, et al. Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes. 2011; 60: 1493–1503.